OpenEvidence revenue: a free app for doctors that sells ads
OpenEvidence revenue reached about $100M a year by January 2026 (media-reported), when the free medical AI search engine for doctors raised $250M at a $12B valuation. It earns from pharma ads.
| Revenue | About $8.3M a month (calc: $100M a year / 12, Jan 2026)Calc from media-reported annual revenue Source, 2026-01 |
|---|---|
| Team size | Not disclosed |
| Pricing | Free for verified US clinicians; revenue from advertisingMedia-reported via Crunchbase News Source, 2026-01 |
| Founded | 2022 |
| Founder | Daniel Nadler |
OpenEvidence revenue does not come from doctors. The AI medical search engine is free for verified clinicians and earns from pharmaceutical and medical device advertising (media-reported, Crunchbase News). It reached about $100M in annual revenue by January 2026, the same month it raised $250M at a $12B valuation. Daniel Nadler founded it in 2022. It is the only ad-supported business in this library’s health cases, and one of the few anywhere in AI.
What is OpenEvidence, and who uses it?
OpenEvidence is a search engine that answers clinical questions with citations to medical journals and guidelines. Daniel Nadler founded it in 2022 (Fierce Healthcare). In July 2025 the company said more than 40% of US physicians used the platform, with more than 65,000 new verified clinician registrations each month and use in over 10,000 hospitals and medical centers (founder-reported, Fierce Healthcare). Nadler said growth came from doctors telling other doctors.
“These copilots are eventually going to get there, but then you differentiate around content and partnerships” — Daniel Nadler (founder-reported, Fierce Healthcare)
How does OpenEvidence make money without charging doctors?
OpenEvidence sells advertising to drug and device makers who want to reach physicians. Doctors use the product for free, and the platform does not charge per seat (media-reported, Crunchbase News). Physician attention is one of the most valuable audiences in advertising, which is why a free tool used by a large share of US doctors can earn nine figures. Team size and total revenue to date are not disclosed.
How much revenue does OpenEvidence earn now?
OpenEvidence reached about $100M in annual revenue by January 2026, about $8.3M a month (calc) (media-reported, Crunchbase News). Sacra estimated about $300M in annualized revenue by July 2026 (third-party estimate, Sacra); that is an analyst estimate, not a number the company published. Valuations moved even faster than revenue: $3.5B in July 2025 and $12B in January 2026 (media-reported, Fierce Healthcare).
| Date | Event | Source |
|---|---|---|
| 2022 | Founded by Daniel Nadler | Fierce Healthcare |
| Jul 2025 | $210M at $3.5B; 40%+ of US physicians | Fierce Healthcare |
| Jan 2026 | $250M Series D at $12B; about $100M annual revenue | Fierce Healthcare, Crunchbase News |
| Jul 2026 | About $300M annualized (estimate) | Sacra |
How does OpenEvidence differ from Abridge and Freed?
OpenEvidence and the AI scribes sell to the same doctors but get paid by different people. Abridge sells to large health systems, which buy it to cut documentation time. Freed sells a monthly subscription directly to individual clinicians. OpenEvidence charges neither: advertisers pay. That lets it spread without procurement cycles or credit cards, which helps explain how it reached a large share of US physicians so quickly.
Our reading: the ad model is OpenEvidence’s growth engine and its biggest risk. A free tool with no sales cycle can reach almost every doctor. But its revenue depends on pharma marketing budgets and on doctors trusting that ads do not shape answers. Abridge and Freed earn less per user but are paid by the people who use them.
What can health AI founders learn from OpenEvidence?
- Free can beat enterprise sales. OpenEvidence reached more than 40% of US physicians without charging them, so no hospital had to approve it.
- The audience can be the product. Physician attention is valuable enough to advertisers to fund a nine-figure business.
- Citations build trust. Answers tied to journals and guidelines suit a profession trained to check sources.
- Ads need a wall. An ad-funded clinical tool has to keep advertising clearly separate from answers to keep doctors’ trust.
Frequently asked questions
What is OpenEvidence revenue?
OpenEvidence reached about $100M in annual revenue by January 2026 (media-reported, Crunchbase News). Sacra estimated about $300M in annualized revenue in July 2026, which is a third-party estimate, not a company figure.
How does OpenEvidence make money?
OpenEvidence is free for verified clinicians and makes money from pharmaceutical and medical device advertising, not from per-seat fees (media-reported, Crunchbase News).
What is the OpenEvidence valuation?
OpenEvidence raised a $250M Series D at a $12B valuation in January 2026, co-led by Thrive Capital and DST Global (media-reported, Fierce Healthcare). In July 2025 it had raised $210M at $3.5B.
How many doctors use OpenEvidence?
OpenEvidence said in July 2025 that more than 40% of US physicians use it, with more than 65,000 new verified clinician registrations a month (founder-reported, via Fierce Healthcare).
Sources
- OpenEvidence raises $210M, unveils AI agents built for advanced medical research – Fierce Healthcare, 2025-07
- OpenEvidence clinches $250M series D as AI platform sees explosive growth with doctors – Fierce Healthcare, 2026-01
- OpenEvidence, an AI-powered brain extender for doctors, doubles valuation to $12B with $250M Series D – Crunchbase News, 2026-01
- OpenEvidence revenue, valuation & funding – Sacra, 2026-07